High mobility Group A1 and cancer: Potential biomarker and therapeutic target

Sandeep N. Shah, Linda M Smith Resar

Research output: Contribution to journalArticle

Abstract

The High Mobility Group A1 (HMGA1, formerly HMG-I/Y) gene is highly expressed during embryogenesis and in virtually all aggressive human cancers studied to date, although its role in these settings is only beginning to emerge. Moreover, high levels of expression portend a poor prognosis in some tumors. Increasing evidence suggests that the HMGA1 protein functions as a master regulator with a critical role in normal development and tumor progression in diverse malignancies. These proteins contain AT-hook DNA binding domains that mediate binding to AT-rich regions of chromatin. After binding to DNA, HMGA1 alters DNA structure, and orchestrates the assembly of a transcriptional complex or "enhanceosome" to regulate gene expression. Previous studies indicate that HMGA1 participates in regulating fundamental cellular processes, including transcription, cell cycle progression, embryonic development, neoplastic transformation, differentiation, senescence, viral integration, and DNA repair by virtue of its ability to interact with other proteins, bind to DNA, and modulate gene expression. Recent studies also link HMGA1 expression to poor differentiation status and a refractory, stem cell-like state in aggressive cancers. Together, these findings suggest that HMGA1 could serve as a useful biomarker and therapeutic target in advanced malignancies. Here, we focus on prior studies implicating HMGA1 in the pathogenesis of refractory human tumors arising from diverse tissues and its potential role as a biomarker. We also review previous attempts to target HMGA1 pathways in cancer. Further study of HMGA1 promises to have a major impact on our ability to understand and treat cancer.

Original languageEnglish (US)
Pages (from-to)567-579
Number of pages13
JournalHistology and Histopathology
Volume27
Issue number5
StatePublished - May 2012

Fingerprint

Tumor Biomarkers
Neoplasms
Therapeutics
DNA
Embryonic Development
AT-Hook Motifs
Biomarkers
AT Rich Sequence
Virus Integration
Gene Expression
Proteins
Viral DNA
DNA Repair
Chromatin
Cell Cycle
Stem Cells

Keywords

  • Biomarker
  • Cancer
  • HMGA1
  • Therapeutic target
  • Tumor progression

ASJC Scopus subject areas

  • Histology
  • Pathology and Forensic Medicine

Cite this

High mobility Group A1 and cancer : Potential biomarker and therapeutic target. / Shah, Sandeep N.; Smith Resar, Linda M.

In: Histology and Histopathology, Vol. 27, No. 5, 05.2012, p. 567-579.

Research output: Contribution to journalArticle

@article{43e2b56e824a4779b9f252abed4b5bfa,
title = "High mobility Group A1 and cancer: Potential biomarker and therapeutic target",
abstract = "The High Mobility Group A1 (HMGA1, formerly HMG-I/Y) gene is highly expressed during embryogenesis and in virtually all aggressive human cancers studied to date, although its role in these settings is only beginning to emerge. Moreover, high levels of expression portend a poor prognosis in some tumors. Increasing evidence suggests that the HMGA1 protein functions as a master regulator with a critical role in normal development and tumor progression in diverse malignancies. These proteins contain AT-hook DNA binding domains that mediate binding to AT-rich regions of chromatin. After binding to DNA, HMGA1 alters DNA structure, and orchestrates the assembly of a transcriptional complex or {"}enhanceosome{"} to regulate gene expression. Previous studies indicate that HMGA1 participates in regulating fundamental cellular processes, including transcription, cell cycle progression, embryonic development, neoplastic transformation, differentiation, senescence, viral integration, and DNA repair by virtue of its ability to interact with other proteins, bind to DNA, and modulate gene expression. Recent studies also link HMGA1 expression to poor differentiation status and a refractory, stem cell-like state in aggressive cancers. Together, these findings suggest that HMGA1 could serve as a useful biomarker and therapeutic target in advanced malignancies. Here, we focus on prior studies implicating HMGA1 in the pathogenesis of refractory human tumors arising from diverse tissues and its potential role as a biomarker. We also review previous attempts to target HMGA1 pathways in cancer. Further study of HMGA1 promises to have a major impact on our ability to understand and treat cancer.",
keywords = "Biomarker, Cancer, HMGA1, Therapeutic target, Tumor progression",
author = "Shah, {Sandeep N.} and {Smith Resar}, {Linda M}",
year = "2012",
month = "5",
language = "English (US)",
volume = "27",
pages = "567--579",
journal = "Histology and Histopathology",
issn = "0213-3911",
publisher = "Histology and Histopathology",
number = "5",

}

TY - JOUR

T1 - High mobility Group A1 and cancer

T2 - Potential biomarker and therapeutic target

AU - Shah, Sandeep N.

AU - Smith Resar, Linda M

PY - 2012/5

Y1 - 2012/5

N2 - The High Mobility Group A1 (HMGA1, formerly HMG-I/Y) gene is highly expressed during embryogenesis and in virtually all aggressive human cancers studied to date, although its role in these settings is only beginning to emerge. Moreover, high levels of expression portend a poor prognosis in some tumors. Increasing evidence suggests that the HMGA1 protein functions as a master regulator with a critical role in normal development and tumor progression in diverse malignancies. These proteins contain AT-hook DNA binding domains that mediate binding to AT-rich regions of chromatin. After binding to DNA, HMGA1 alters DNA structure, and orchestrates the assembly of a transcriptional complex or "enhanceosome" to regulate gene expression. Previous studies indicate that HMGA1 participates in regulating fundamental cellular processes, including transcription, cell cycle progression, embryonic development, neoplastic transformation, differentiation, senescence, viral integration, and DNA repair by virtue of its ability to interact with other proteins, bind to DNA, and modulate gene expression. Recent studies also link HMGA1 expression to poor differentiation status and a refractory, stem cell-like state in aggressive cancers. Together, these findings suggest that HMGA1 could serve as a useful biomarker and therapeutic target in advanced malignancies. Here, we focus on prior studies implicating HMGA1 in the pathogenesis of refractory human tumors arising from diverse tissues and its potential role as a biomarker. We also review previous attempts to target HMGA1 pathways in cancer. Further study of HMGA1 promises to have a major impact on our ability to understand and treat cancer.

AB - The High Mobility Group A1 (HMGA1, formerly HMG-I/Y) gene is highly expressed during embryogenesis and in virtually all aggressive human cancers studied to date, although its role in these settings is only beginning to emerge. Moreover, high levels of expression portend a poor prognosis in some tumors. Increasing evidence suggests that the HMGA1 protein functions as a master regulator with a critical role in normal development and tumor progression in diverse malignancies. These proteins contain AT-hook DNA binding domains that mediate binding to AT-rich regions of chromatin. After binding to DNA, HMGA1 alters DNA structure, and orchestrates the assembly of a transcriptional complex or "enhanceosome" to regulate gene expression. Previous studies indicate that HMGA1 participates in regulating fundamental cellular processes, including transcription, cell cycle progression, embryonic development, neoplastic transformation, differentiation, senescence, viral integration, and DNA repair by virtue of its ability to interact with other proteins, bind to DNA, and modulate gene expression. Recent studies also link HMGA1 expression to poor differentiation status and a refractory, stem cell-like state in aggressive cancers. Together, these findings suggest that HMGA1 could serve as a useful biomarker and therapeutic target in advanced malignancies. Here, we focus on prior studies implicating HMGA1 in the pathogenesis of refractory human tumors arising from diverse tissues and its potential role as a biomarker. We also review previous attempts to target HMGA1 pathways in cancer. Further study of HMGA1 promises to have a major impact on our ability to understand and treat cancer.

KW - Biomarker

KW - Cancer

KW - HMGA1

KW - Therapeutic target

KW - Tumor progression

UR - http://www.scopus.com/inward/record.url?scp=84859306174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859306174&partnerID=8YFLogxK

M3 - Article

C2 - 22419021

AN - SCOPUS:84859306174

VL - 27

SP - 567

EP - 579

JO - Histology and Histopathology

JF - Histology and Histopathology

SN - 0213-3911

IS - 5

ER -